SCHEMBL4344585

SCHEMBL4344585

CC(=O)Oc1ccc(F)cc1-c1cc(C(N)=O)c(NC(N)=O)[nH]1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 7/20 0.45
CCNT1 O60563 4/20 0.38
CDK9 P50750 4/20 0.38
AMY1A P0DUB6 1/20 0.36
MEN1 O00255 1/20 0.35
IKBKB O14920 1/20 0.35
JAK2 O60674 1/20 0.35
EIF2AK2 P19525 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
TOP1 P11387 1/20 0.34
CDC7 O00311 1/20 0.34
CFD P00746 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SLC9A1 P19634 1/20 0.33
NR3C1 P04150 1/20 0.33
PGR P06401 1/20 0.33
NR3C2 P08235 1/20 0.33
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197511 0.88 BRD4 (0.46) BRD4CCNT1CDK9CDC7SLC9A1
SCHEMBL2198565 0.87 BRD4 (0.50) BRD4TDP1TOP1CDC7ALDH1A1
SCHEMBL4352395 0.86 BRD4 (0.42) BRD4AMY1AMEN1JAK2KMT2A
SCHEMBL2196441 0.85 BRD4 (0.44) BRD4CCNT1CDK9MEN1KMT2A
SCHEMBL2198985 0.83 MAPT (0.47) BRD4CCNT1CDK9MEN1IKBKB
SCHEMBL2197617 0.82 BRD4 (0.41) BRD4CCNT1CDK9MEN1IKBKB
SCHEMBL4344141 0.81 BRD4 (0.41) BRD4CCNT1CDK9MEN1IKBKB
SCHEMBL2198205 0.81 BRD4 (0.40) BRD4CCNT1CDK9MEN1IKBKB
SCHEMBL2195955 0.81 CDK9 (0.42) BRD4CCNT1CDK9CDC7
SCHEMBL2200320 0.81 BRD4 (0.41) BRD4CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2116530-B1 NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO LTD (JP) 2012-11-14 EP disclosed
US-7977371-B2 Pyrrole derivative having ureido group and aminocarbonyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-07-12 US disclosed
US-7977371-B2 Pyrrole derivative having ureido group and aminocarbonyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-07-12 US disclosed
US-20100099675-A1 NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-04-22 US disclosed
US-20100099675-A1 NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-04-22 US disclosed
EP-2116530-A1 NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099675-A1 NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS UACA, IL6, IL6ST BRD4 497/4885CCNT1 1261/4885CDK9 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.